Avadel PharmaceuticalsAVDL
13F holders, Q4 2025 (December 31)2holders −1
0new positions
1sold out
$21.55avg. 13F price*
At the end of Q4 2025, 2 institutions reported holding Avadel Pharmaceuticals plc (AVDL) in their 13F filings, down 1 from Q3 2025. 0 opened new positions and 1 sold out. The largest holders were Knoll Capital Management, LLC ($12.9M) and Huntington National Bank ($16).
- Company
- Avadel Pharmaceuticals plc
- CUSIP
- 05337M104
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $2.1M |
All 13F filers, Q3 2025 → Q4 2025: 137,500 shares sold, net −137,500 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Knoll Capital Management, LLC | 5.93% | No change | 600,000 | $12.9M |
| Huntington National Bank | 0.00% | No change | 1 | $16 |
"% of holder's portfolio" is AVDL's weight in each manager's 13F, not the share of Avadel Pharmaceuticals plc the manager owns.